Market capitalization | $103.18b |
Enterprise Value | $143.58b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 10.30 |
EV/Sales (TTM) EV/Sales | 2.97 |
P/S ratio (TTM) P/S ratio | 2.14 |
P/B ratio (TTM) P/B ratio | 6.30 |
Dividend yield | 4.77% |
Last dividend (FY24) | $2.42 |
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
25 Analysts have issued a Bristol-Myers Squibb forecast:
25 Analysts have issued a Bristol-Myers Squibb forecast:
Dec '24 |
+/-
%
|
||
Revenue | 48,300 48,300 |
7%
7%
|
|
Gross Profit | 27,432 27,432 |
8%
8%
|
|
EBITDA | 18,489 18,489 |
1%
1%
|
EBIT (Operating Income) EBIT | 8,938 8,938 |
6%
6%
|
Net Profit | -8,948 -8,948 |
212%
212%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. The firm offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
Head office | United States |
CEO | Christopher Boerner |
Employees | 34,100 |
Founded | 1933 |
Website | www.bms.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.